Literature DB >> 28442294

Who benefits from antimicrobial combination therapy?

Mathias W Pletz1, Stefan Hagel2, Christina Forstner3.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28442294     DOI： 10.1016/S1473-3099(17)30233-5

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  4 in total

1.  In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

2.  Mutational Switch-Backs Can Accelerate Evolution of Francisella to a Combination of Ciprofloxacin and Doxycycline.

Authors:  Heer H Mehta; David Ibarra; Christopher J Marx; Craig R Miller; Yousif Shamoo
Journal:  Front Microbiol       Date:  2022-05-09       Impact factor: 6.064

3.  Synergy between Florfenicol and Aminoglycosides against Multidrug-Resistant Escherichia coli Isolates from Livestock.

Authors:  Shukho Kim; Jung Hwa Woo; So Hyun Jun; Dong Chan Moon; Suk-Kyung Lim; Je Chul Lee
Journal:  Antibiotics (Basel)       Date:  2020-04-16

4.  Synergistic bactericidal profiling of prodigiosin extracted from Serratia marcescens in combination with antibiotics against pathogenic bacteria.

Authors:  Nisarg Gohil; Gargi Bhattacharjee; Vijai Singh
Journal:  Microb Pathog       Date:  2020-09-18       Impact factor: 3.738
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.